Tiffany Folse
Primary Care · Mobile, ALNPI 1508492505
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 73 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 18.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $881 and has fallen 91.5% since, to $75 in 2023.
Across 73 payments — averaging $21.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$282
- Biohaven Pharmaceuticals, Inc.$236
- Novo Nordisk$159
- Acadia Pharmaceuticals Inc$106
- Amgen$86
- Eisai Inc.$78
- plus $588 from 21 others
What the payments were for
- Food & beverage$1,535100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 17 | $282 |
| Biohaven Pharmaceuticals, Inc. | 6 | $236 |
| Novo Nordisk | 2 | $159 |
| Acadia Pharmaceuticals Inc | 6 | $106 |
| Amgen(2 entities) | 5 | $86 |
| Eisai Inc. | 4 | $78 |
| Biogen | 4 | $65 |
| Acorda Therapeutics, Inc | 4 | $64 |
| SK Life Science, Inc. | 2 | $47 |
| Novartis | 2 | $44 |
| Alnylam Pharmaceuticals Inc. | 2 | $41 |
| UCB, Inc. | 2 | $36 |
| Neurocrine Biosciences, Inc. | 2 | $32 |
| Johnson & Johnson | 2 | $27 |
| Lundbeck LLC | 1 | $25 |
| Grifols USA, LLC | 1 | $22 |
| Upsher-smith Laboratories LLC | 1 | $21 |
| Avion Pharmaceuticals | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Zogenix Inc. | 1 | $18 |
| Neurelis, Inc. | 1 | $18 |
| AstraZeneca | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| ANI Pharmaceuticals, Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Pfizer | 1 | $13 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$120
- Wegovy$119
How this compares
$1,535 in reported general payments places this provider in the 65th percentile of 159 primary care providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 33 | $706 |
| Methylprednisolone | 13 | $139 |
| Doxycycline Hyclate | 13 | $127 |
| Prednisone | 11 | $26 |
Paid to pharmacies, not to this prescriber.
Other primary care in Mobile
- Brandy McGrawMobile$14K
- Joshua RiversMobile$7K
- Barbara NamanMobile$4K
- Rachael RostasMobile$3K
- Tara ChildersMobile$2K
- Kimberly OchabMobile$1K
- Keith MatthewsOpelika$20K
- Troy HendersonFultondale$18K
- April TateDothan$16K
- Cleo ValdezHuntsville$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.